Clinical Trial Search

Primary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) — 9.0; 38.0 percentage of…

Primary: Change in Mean Daily Step Count From the Baseline Step Count During Two Days After the Surgery to the Hospital Discharge — 1087; 995 mean change in daily steps

Primary: Change in Moderate to Vigorous Activity (MVPA) During Recess — 1.4; 6.2 percentage of time

Primary: Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition — 3.6 Z-score — p=0.004

Primary: Photopic Monocular Best-corrected Distance Visual Acuity (BCDVA) — 0.022; -0.017 logMAR

Primary: Objective 1 Primary Outcome: Change in Minutes of Sedentary Behavior, Light Physical Activity, and Moderate-to-vigorous Physical Activity — 21.4; 7.6; 1.0 Minutes…

Primary: Change From Baseline in Physical Activity — 209.08; 79.84 minutes — p=<0.05

Primary: Immune Response Measuring Increased Numbers of Peptide Specific T Cells as Calculated by the Tetramer Assay. — 0; 0; 0; 0 percent of CD8+ T cells

Primary: Number of Participants With and Without Virological Suppression — 84; 40; 3; 1 Participants

Primary: Thromboembolism — 4.86; 0.29; 2.43; 1.74 %/patient years

Primary: Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 — 5.9; 6.0 days — p=0.0681

Primary: Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment — 11; 19 Number of participants with events

Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants

Primary: Total Pharyngeal Transit Time (With CPAP) — 10.18 seconds — p=<0.05

Primary: Foot Pain at Its Worst at Baseline and Week 6 — 6.4; 5.3; 3.6; 5.4 unit on scale